Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A hypothetical protein H41 was detected, which may repress the Her-2/neu receptor influencing breast cancer, gliomas and prostate tumors.
|
17192923 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the role of oncogenes and growth factors in prostate carcinoma is still unclear, overexpression of the epidermal growth factor receptor (erbB-1) and the proto-oncogene erbB-2 have been reported in prostate tumors, and erbB-2 related to poor prognosis and distant metastasis.
|
9917515 |
1999 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
An examination of HER2 and NF-κB receptor (RANK) coexpression revealed increased levels of both proteins in aggressive prostate tumors and metastatic deposits.
|
27793843 |
2017 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility.
|
15389808 |
2005 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Both wild-type and mutant forms of plexinB1 are potential targets for anti-cancer therapy in prostate tumors that express ErbB2.
|
23775445 |
2013 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
|
18337451 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells.
|
17563746 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Finally, quantitative, competitive reverse transcription polymerase chain reaction (QC-RT-PCR) analysis demonstrated that Ad21 could effectively reduce DU 145 and erbB-2-positive primary prostate tumor contamination in bone marrow cultures.
|
9017419 |
1997 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients.
|
18038879 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy.
|
18645672 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In order to define AR, erbB-1 and erbB-2 in human prostate neoplasms 36 benign prostatic hyperplasia, 46 prostatic carcinoma and 12 normal prostate gland samples were analysed.
|
14654929 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1alpha, HER-2/neu, bFGF and increased PTEN level.
|
17611019 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study, we show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis.
|
21930937 |
2011 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides.
|
11222871 |
2001 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.
|
18767028 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
|
17363613 |
2007 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Of the 10 tumor samples analyzed by fluorescence in situ hybridization, genomic amplification of the Her-2/neu locus was not detected in any of the metastatic prostate tumors.
|
15269147 |
2004 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Of the 31 prostate tumors in the untreated group 9 (29%) showed high HER-2/neu expression versus 15 of 30 (50%) in the treated and 17 of 20 (85%) in the androgen independent groups.
|
11547123 |
2001 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Peripheral blood lymphocytes (PBL) were then isolated from six consecutive human leukocyte antigen (HLA) A2+ patients with HER2/neu+ prostate tumors.
|
15547716 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Pharmacological inhibition of ErbB2 and c-Met reduced the ability of prostate tumor progenitor cells to undergo self-renewal in vitro.
|
23348745 |
2013 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
|
16984552 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
|
16984552 |
2006 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Previous studies have reported widely divergent rates for HER2 expression in primary prostate tumors, probably owing to significant methodologic differences in the studies.
|
11488070 |
2001 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Previous work in animal models showed that p110α was the key isoform in breast tumors driven by oncogenes, including MT and HER2, while p110β was key in prostate tumors driven by Pten loss.
|
24991009 |
2014 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The expression level was similar in all prostate tumor types and corresponded to the level of expression in breast carcinomas without ERBB2 amplification.
|
11786427 |
2002 |